Department of Medicine

Department of Medicine

  Division of Hematology/Oncology

[Return To Index page]
photo G. Van Londen, MD, MS

Associate Professor of Medicine


Phone: 412-692-2382

Office: Magee Womens Hospital of UPMC
300 Halket Street, Room 3526
Pittsburgh, PA 15213
Phone: 412-692-2382
Fax: 412-641-6461
Administrative Assistant:
MaryTeresa Dujmic
Address: 300 Halkett Street
Magee Womens Hospital, Room I 410
Pittsburgh, PA 15213
Phone: 412-641-3494
Fax: 412-641-6461
Education and Training
MD, University Medical Center of Utrecht, Netherlands, 2000
Master of Science, University of Pittsburgh, 2009
Research Interest
She performs her own research, but also collaborates on research that is highly relevant to (older) cancer survivors. Her main focus points are the assessment and management of 1) adverse effects of and adherence to self-administered cancer therapies and 2) needs of post-treatment cancer survivors.
Clinical Interest
Dr. van Londen is a dually ABIM certified medical oncologist and geriatrician.

She provides care at and is the director of UPMC's Cancer LiveWell Survivorship Programs (located at Magee-Womens Hospital of UPMC and Hillman Cancer Center of UPMC CancerCenter.

She also has special expertise in the care of older patients with newly diagnosed, early stage or advanced breast cancer.
Educational Interest
Dr. van Londen educates cancer survivors as well as health care providers about survivorship and geriatric oncology topics.
For my complete bibliography, Click Here.
Selected Publications:
Van Londen GJ, Perera S, Vujevich KT, Sereika SM, Bhattacharya R. The effect of risedronate on hip structural geometry in chemotherapy-induced postmenopausal women with or without use of aromatase inhibitors: a 2-year tria. Bone. 2010; 46(3): 655-659.
Van Londen GJ, Perera L, Vujevich KT, Sereika SM, Bhattacharya R. Effect of risedronate on hip structural geometry: a 1-year, double-blind trial in chemotherapy-induced postmenopausal women. Bone. 2008; 43(2): 274-278.
Van Londen GJ, Mascarenhas B, Kirkwood JM. Rhabdomyolysis, when observed with high-dose interferon-alfa (HDI) therapy, does not always exclude resumption of HDI. Journal of Clinical Oncology. 2001; 19(17): 3794-3799.
Van Londen GJ, Beckjord EB, Dew MA, Cooper KL, Davidson NE. Associations between adjuvant endocrine therapy and onset of physical and emotional concerns among breast cancer survivors. Supportive Care in Cancer. 2014; 22(4): 937-945.
Van Londen GJ, Perera S, Vujevich K, Rastogi P, Lembersky B, Brufsky A. The impact of an aromatase inhibitor on body composition and gonadal hormone levels in women with breast cancer. Breast cancer research and treatment. 2011; 125(2): 441-446.
Beckjord EB, Reynolds KA, Van Londen GJ, Burns R, Singh R, Arvey SR. Population-level trends in posttreatment cancer survivors’ concerns and associated receipt of care: results from the 2006 and 2010 LIVESTRONG surveys. Journal of psychosocial oncology. 2014; 32(2): 125-151.
Levy ME, Perera S, Van Londen GJ, Nelson JB, Clay CA, Greenspan SL. Physical function changes in prostate cancer patients on androgen deprivation therapy: a 2-year prospective study. Urology. 2008; 71(4): 735-739.
Tadic SD, Elm MS, Li H, Van Londen GJ, Subbotin VM, Whitecomb DC. Sex differences in hepatic gene expression in a rat model of ethanol-induced liver injury. Journal of Applied Physiology. 2002; 93(3): 1057-1068.
Stroes ES, Van Faassen EE, Van Londen GJ, Rabelink TJ. Oxygen radical stress in vascular disease: the role of endothelial nitric oxide synthase. Journal of cardiovascular pharmacology. 1997; 32: S14-21.
Van Londen GJ, Levy ME, Perera S, Nelson JB, Greenspan. Body composition changes during androgen deprivation therapy for prostate cancer: a 2-year prospective study. Critical reviews in oncology/hematology. 2008; 68(2): 172-177.
Notable Achievements
University og Pittsburgh Honors Convocation, 2017
Member of 3 ASCO Committees, 2015-now